507 related articles for article (PubMed ID: 9632354)
1. Molecular modeling studies of the DNA-topoisomerase I ternary cleavable complex with camptothecin.
Fan Y; Weinstein JN; Kohn KW; Shi LM; Pommier Y
J Med Chem; 1998 Jun; 41(13):2216-26. PubMed ID: 9632354
[TBL] [Abstract][Full Text] [Related]
2. Differential induction of topoisomerase I-DNA cleavage complexes by the indenoisoquinoline MJ-III-65 (NSC 706744) and camptothecin: base sequence analysis and activity against camptothecin-resistant topoisomerases I.
Antony S; Jayaraman M; Laco G; Kohlhagen G; Kohn KW; Cushman M; Pommier Y
Cancer Res; 2003 Nov; 63(21):7428-35. PubMed ID: 14612542
[TBL] [Abstract][Full Text] [Related]
3. Characterization of a novel topoisomerase I mutation from a camptothecin-resistant human prostate cancer cell line.
Urasaki Y; Laco GS; Pourquier P; Takebayashi Y; Kohlhagen G; Gioffre C; Zhang H; Chatterjee D; Pantazis P; Pommier Y
Cancer Res; 2001 Mar; 61(5):1964-9. PubMed ID: 11280753
[TBL] [Abstract][Full Text] [Related]
4. Mechanisms of resistance to topoisomerase I-targeting drugs.
Rasheed ZA; Rubin EH
Oncogene; 2003 Oct; 22(47):7296-304. PubMed ID: 14576839
[TBL] [Abstract][Full Text] [Related]
5. Effect of E-ring modifications in camptothecin on topoisomerase I inhibition: a quantum mechanics treatment.
Xiao X; Cushman M
J Org Chem; 2005 Nov; 70(23):9584-7. PubMed ID: 16268636
[TBL] [Abstract][Full Text] [Related]
6. Human topoisomerase I inhibition: docking camptothecin and derivatives into a structure-based active site model.
Laco GS; Collins JR; Luke BT; Kroth H; Sayer JM; Jerina DM; Pommier Y
Biochemistry; 2002 Feb; 41(5):1428-35. PubMed ID: 11814334
[TBL] [Abstract][Full Text] [Related]
7. The camptothecin-resistant topoisomerase I mutant F361S is cross-resistant to antitumor rebeccamycin derivatives. A model for topoisomerase I inhibition by indolocarbazoles.
Bailly C; Carrasco C; Hamy F; Vezin H; Prudhomme M; Saleem A; Rubin E
Biochemistry; 1999 Jul; 38(27):8605-11. PubMed ID: 10393535
[TBL] [Abstract][Full Text] [Related]
8. Use of camptothecin-resistant mammalian cell lines to evaluate the role of topoisomerase I in the antiproliferative activity of the indolocarbazole, NB-506, and its topoisomerase I binding site.
Urasaki Y; Laco G; Takebayashi Y; Bailly C; Kohlhagen G; Pommier Y
Cancer Res; 2001 Jan; 61(2):504-8. PubMed ID: 11212241
[TBL] [Abstract][Full Text] [Related]
9. Action models for the antitumor drug camptothecin: formation of alkali-labile complex with DNA and inhibition of human DNA topoisomerase I.
Streltsov SA
J Biomol Struct Dyn; 2002 Dec; 20(3):447-54. PubMed ID: 12437383
[TBL] [Abstract][Full Text] [Related]
10. Persistence of camptothecin analog-topoisomerase I-DNA ternary complexes: a molecular dynamics study.
Siu FM; Che CM
J Am Chem Soc; 2008 Dec; 130(52):17928-37. PubMed ID: 19035632
[TBL] [Abstract][Full Text] [Related]
11. Structures of three classes of anticancer agents bound to the human topoisomerase I-DNA covalent complex.
Staker BL; Feese MD; Cushman M; Pommier Y; Zembower D; Stewart L; Burgin AB
J Med Chem; 2005 Apr; 48(7):2336-45. PubMed ID: 15801827
[TBL] [Abstract][Full Text] [Related]
12. Hydrophilic camptothecin analogs that form extremely stable cleavable complexes with DNA and topoisomerase I.
Wadkins RM; Bearss D; Manikumar G; Wani MC; Wall ME; Von Hoff DD
Cancer Res; 2004 Sep; 64(18):6679-83. PubMed ID: 15374984
[TBL] [Abstract][Full Text] [Related]
13. Novel 7-alkyl methylenedioxy-camptothecin derivatives exhibit increased cytotoxicity and induce persistent cleavable complexes both with purified mammalian topoisomerase I and in human colon carcinoma SW620 cells.
Valenti M; Nieves-Neira W; Kohlhagen G; Kohn KW; Wall ME; Wani MC; Pommier Y
Mol Pharmacol; 1997 Jul; 52(1):82-7. PubMed ID: 9224816
[TBL] [Abstract][Full Text] [Related]
14. A structural model for the ternary cleavable complex formed between human topoisomerase I, DNA, and camptothecin.
Kerrigan JE; Pilch DS
Biochemistry; 2001 Aug; 40(33):9792-8. PubMed ID: 11502172
[TBL] [Abstract][Full Text] [Related]
15. SUMO-1 conjugation to intact DNA topoisomerase I amplifies cleavable complex formation induced by camptothecin.
Horie K; Tomida A; Sugimoto Y; Yasugi T; Yoshikawa H; Taketani Y; Tsuruo T
Oncogene; 2002 Nov; 21(52):7913-22. PubMed ID: 12439742
[TBL] [Abstract][Full Text] [Related]
16. Enhancement of camptothecin-induced topoisomerase I cleavage complexes by the acetaldehyde adduct N2-ethyl-2'-deoxyguanosine.
Antony S; Theruvathu JA; Brooks PJ; Lesher DT; Redinbo M; Pommier Y
Nucleic Acids Res; 2004; 32(18):5685-92. PubMed ID: 15498925
[TBL] [Abstract][Full Text] [Related]
17. DNA cleavage by topoisomerase I in the presence of indolocarbazole derivatives of rebeccamycin.
Bailly C; Riou JF; Colson P; Houssier C; Rodrigues-Pereira E; Prudhomme M
Biochemistry; 1997 Apr; 36(13):3917-29. PubMed ID: 9092822
[TBL] [Abstract][Full Text] [Related]
18. Total and semisynthesis and in vitro studies of both enantiomers of 20-fluorocamptothecin.
Tangirala RS; Dixon R; Yang D; Ambrus A; Antony S; Agama K; Pommier Y; Curran DP
Bioorg Med Chem Lett; 2005 Nov; 15(21):4736-40. PubMed ID: 16140529
[TBL] [Abstract][Full Text] [Related]
19. Camptothecin conjugated with DNA minor-groove binder netropsin: enhanced lactone stability, inhibition of human DNA topoisomerase I and antiproliferative activity.
Sukhanova A; Grokhovsky S; Zhuze A; Devy J; Pluot M; Oleinikov V; Nabiev I
Anticancer Res; 2003; 23(3B):2609-15. PubMed ID: 12894548
[TBL] [Abstract][Full Text] [Related]
20. Identification of mutations at DNA topoisomerase I responsible for camptothecin resistance.
Wang LF; Ting CY; Lo CK; Su JS; Mickley LA; Fojo AT; Whang-Peng J; Hwang J
Cancer Res; 1997 Apr; 57(8):1516-22. PubMed ID: 9108454
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
